Sequence Inc Ncbionetwork Org Sequence lifescience™, inc. was established in 2021 with a mission of becoming a premier allograft tissue solutions facility. since inception our goal is to work closely with our partners to provide the highest caliber human cell and tissue products (hct ps) in the industry. Sequence is an engineering consulting firm specializing in ensuring that facilities and manufacturing processes are designed and tested to meet end user requirements. leveraging deep process knowledge, our consultants provide valuable input to ensure compliance and efficiency from conceptual design through licensure.
Video Sequence Inc On Linkedin Sequencelife Sequence inc. provides turn key consulting solutions and services for the biopharmaceutical manufacturing industry with a focus on commissioning, qualification and validation (cqv) and digital. Sequence lifescience, inc. sequence lifescience, inc. (texas tax id: 32077546797) was incorporated on 01 01 2020 in texas. their business is recorded as foreign profit corporation. the company's current operating status is active. View company leaders and background information for sequence lifescience, inc. search our database of over 100 million company and executive profiles. Sequence life science company profile with ownership history, investor relationships, and business overview.
Sequencelife Sequence Inc View company leaders and background information for sequence lifescience, inc. search our database of over 100 million company and executive profiles. Sequence life science company profile with ownership history, investor relationships, and business overview. Starting as a small computer validation consulting firm for the biopharma industry in 2002, sequence, inc. has transformed into a fully comprehensive consulting organization that provides turnkey cqv and digital solutions for facilities, utilities, equipment, computerized systems and labs. Ceo of sequence lifescience]. “by using a matched controls, modified platform trial, we can generate high quality data that will advance the field and inform clinical best practices,” said dr thomas serena, founder and ceo serenagroup inc. and lead investigator for the study. Sequence™ lifescience, inc. was established in 2021 with the goal of being a premier human tissue allograft processing facility. working closely with partners, our skilled operations and quality teams provide the highest caliber human cell and tissue products (hct ps). Last week, we announced the acquisition of rebound, a full thickness placental derived allograft matrix product, from sequence lifescience, inc. (“sequence”). we have sold in excess of $9 million of rebound, which is reimbursed in pos 11, 12, and 32 via hcpcs code q4296 when medically necessary.
Comments are closed.